N-(3,4-difluorophenyl)-2-(benzylthio)-4-oxo-3-phenyl-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidine-6(4H)-carboxamide | 1016975-24-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: N-(3,4-difluorophenyl)-2-(benzylthio)-4-oxo-3-phenyl-3,5,7,8-tetrahydropyrido[4,3-d]pyrimidine-6(4H)-carboxamide
• 英文别名: 2-benzylsulfanyl-N-(3,4-difluorophenyl)-4-oxo-3-phenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-6-carboxamide
• CAS: 1016975-24-8
• 化学式: C₂₇H₂₂F₂N₄O₂S
• 分子量: 504.56
• InChiKey: HCEBDLNXRZPDEK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  90.3
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20180009796A1

  公开（公告）日：2018-01-11

  The compounds of Formula I act as MGAT2 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  Formula I的化合物作为MGAT2抑制剂，可用于预防、治疗或作为高脂血症、糖尿病和肥胖的治疗药物。
• [EN] PYRIMIDIN-4(3H)-ONE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRIMIDIN-4(3H)-ONE
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010095767A1

  公开（公告）日：2010-08-26

  The present invention relates to a compound represented by a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 represents lower alkyl or the like; R2 represents phenyl or the like; R represents a halogen atom or the like; X represents an oxygen atom or the like; Y1, Y2, Y3 and Y4 represent CH or the like; l represents an integer of from 0 to 3; m and n each represent an integer of 1 or 2; p represents an integer of from 0 to 2; and q represents an integer of from 1 to 3.

  本发明涉及一种由式(I)表示的化合物或其药学上可接受的盐，其中R1代表低碳烷基或类似物; R2代表苯基或类似物; R代表卤素原子或类似物; X代表氧原子或类似物; Y1、Y2、Y3和Y4代表CH或类似物; l表示0到3的整数; m和n各表示1或2的整数; p表示0到2的整数; q表示1到3的整数。
• PYRIMIDIN-4-(3H)-ONE DERIVATIVES
  申请人：Arakawa Keisuke

  公开号：US20110275647A1

  公开（公告）日：2011-11-10

  The present invention relates to a compound represented by a formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 represents lower alkyl or the like; R 2 represents phenyl or the like; R represents a halogen atom or the like; X represents an oxygen atom or the like; Y 1 , Y 2 , Y 3 and Y 4 represent CH or the like; l represents an integer of from 0 to 3; m and n each represent an integer of 1 or 2; p represents an integer of from 0 to 2; and q represents an integer of from 1 to 3.

  本发明涉及一种由式（I）表示的化合物或其药学上可接受的盐，其中R1代表较低的烷基或类似物；R2代表苯基或类似物；R代表卤素原子或类似物；X代表氧原子或类似物；Y1、Y2、Y3和Y4代表CH或类似物；l表示0到3的整数；m和n各代表1或2的整数；p表示0到2的整数；q表示1到3的整数。
• COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP2078719A1

  公开（公告）日：2009-07-15

  The present invention relates to a bicyclic pyrimidine compound of the following formula (I) or a salt thereof. wherein R1 is lower alkyl, cyclic lower alkyl. etc.; R2 is H, lower alkyl, lower alkenyl, etc.; R3 is H, lower alkyl, lower alkenyl, etc.; X is O, S or -N(R4)-; R4 is H or lower alkyl; or R2 and R4 may combine each other to form cyclic amino; Y is amido, keto, sulfonyl, etc.; R5 is H or lower alkyl; Z is O or S; m and n are 1 or 2. Said compound (I) or a salt thereof have MGAT inhibitory activity, and are useful as an agent for treatment or prophylaxis of adiposity, metabolic syndromes, hyperlipidemia, hyper neutral lipemia, hyper VLDL-mia, hyper fatty acidemia, diabetes mellitus, arteriosclerosis.

  本发明涉及下式（I）的双环嘧啶化合物或其盐。 其中 R1 是低级烷基、环状低级烷基等；R2 是 H、低级烷基、低级烯基等；R3 是 H、低级烷基、低级烯基等；X 是 O、S 或 -N(R4)-；R4 是 H 或低级烷基；或 R2 和 R4 可相互结合形成环状氨基；Y 是氨基、酮基、磺酰基等；R5 是 H 或低级烷基；Z 是 O 或 S；m 和 n 是 1 或 2。所述化合物(I)或其盐具有 MGAT 抑制活性，可用于治疗或预防肥胖症、代谢综合征、高脂血症、高中性脂血症、高 VLDL-血症、高脂肪酸血症、糖尿病、动脉硬化。
• EP3097101B1
  申请人：——

  公开号：EP3097101B1

  公开（公告）日：2020-12-23